Insulin-like growth factor I (Igf-1) gene polymorphism in patients with non-metastatic breast cancer
Copyright policy )Insulin-like growth factor I (Igf-1) gene polymorphism in patients with non-metastatic breast cancer
We aimed to assess the association between IGF-I gene (CA repeats) polymorphism in breast cancer patients and their clinicopathological features, as well as disease recurrence and survival. Seventy-six non-metastatic breast cancer patients were enrolled in the present study. The IGF-I (CA) repeats were studied with polymerase chain reaction by using proper primers belonging to these gene areas from DNA samples. Results show that the non 19- non 19 homozygote were more common in patients without lymph node involvement (p=0.04), with low histological grade (p=0.04), with positive hormone receptor status (p=0.01), and in patients without recurrence (p=0.06). These results suggest that the non 19-non 19 carriers have some favorable prognostic factors, and IGF-I gene polymorphism (CA repeats) may affect disease recurrence and overall survival.
- Pamukkale University Turkey
genetic analysis, somatomedin, Breast cancer, 80 and over, Insulin-like growth factor, Insulin-Like Growth Factor I, cancer survival, Adult; Aged; Aged, 80 and over; Breast Neoplasms/*genetics/*mortality/pathology; Disease-Free Survival; Female; Humans; Insulin-Like Growth Factor I/*genetics; Middle Aged; Neoplasm Recurrence, Local; *Polymorphism, Genetic; Prognosis, antineoplastic agent, Aged, 80 and over, partial mastectomy, cancer adjuvant therapy, adult, Gene polymorphism, article, mastectomy, adjuvant therapy, Middle Aged, Prognosis, unclassified drug, female, Local, priority journal, Female, insulin like growth factor 1 protein, Adult, overall survival, 610, lymph node dissection, Breast Neoplasms, Disease-Free Survival, breast cancer, Genetic, 616, cancer radiotherapy, Humans, human, Polymorphism, Aged, Polymorphism, Genetic, DNA, major clinical study, axillary lymph node, clinical feature, Neoplasm Recurrence, cancer recurrence, DNA polymorphism, Neoplasm Recurrence, Local, neoplasm
genetic analysis, somatomedin, Breast cancer, 80 and over, Insulin-like growth factor, Insulin-Like Growth Factor I, cancer survival, Adult; Aged; Aged, 80 and over; Breast Neoplasms/*genetics/*mortality/pathology; Disease-Free Survival; Female; Humans; Insulin-Like Growth Factor I/*genetics; Middle Aged; Neoplasm Recurrence, Local; *Polymorphism, Genetic; Prognosis, antineoplastic agent, Aged, 80 and over, partial mastectomy, cancer adjuvant therapy, adult, Gene polymorphism, article, mastectomy, adjuvant therapy, Middle Aged, Prognosis, unclassified drug, female, Local, priority journal, Female, insulin like growth factor 1 protein, Adult, overall survival, 610, lymph node dissection, Breast Neoplasms, Disease-Free Survival, breast cancer, Genetic, 616, cancer radiotherapy, Humans, human, Polymorphism, Aged, Polymorphism, Genetic, DNA, major clinical study, axillary lymph node, clinical feature, Neoplasm Recurrence, cancer recurrence, DNA polymorphism, Neoplasm Recurrence, Local, neoplasm
citations This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).8 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Average influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Average impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Top 10%
Citations provided by BIP!Popularity provided by BIP!